Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
K Merx, MC Müller, S Kreil, T Lahaye, P Paschka… - Leukemia, 2002 - nature.com
The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
Chronic myelogenous leukemia: laboratory diagnosis and monitoring
Rapid developments have occurred both in laboratory medicine and in therapeutic
interventions for the management of patients with chronic myelogenous leukemia (CML) …
interventions for the management of patients with chronic myelogenous leukemia (CML) …
Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients
E Weisberg, JD Griffin - Drug Resistance Updates, 2001 - Elsevier
The tyrosine kinase inhibitor imatinib (ST1571, Glivec) blocks the activity of the BCR/ABL
oncogene and induces hematologic remissions in the majority of patients with chronic …
oncogene and induces hematologic remissions in the majority of patients with chronic …
Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-α therapy or …
JC Chomel, F Brizard, A Veinstein… - Blood, The Journal …, 2000 - ashpublications.org
In recent years, the prognosis of chronic myeloid leukemia (CML) has been greatly improved
either with interferon-(IFN-) therapy or allogeneic bone marrow transplantation (BMT). In …
either with interferon-(IFN-) therapy or allogeneic bone marrow transplantation (BMT). In …
[HTML][HTML] PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal
S Kanodia, E Wieder, S Lu, M Talpaz, G Alatrash… - PLoS …, 2010 - journals.plos.org
Background Interferon-α (IFN) induces complete cytogenetic remission (CCR) in 20–25%
CML patients and in a small minority of patients; CCR persists after IFN is stopped. IFN …
CML patients and in a small minority of patients; CCR persists after IFN is stopped. IFN …
Comprehensive comparison of FISH, RT‐PCR, and RQ‐PCR for monitoring the BCR‐ABL gene after hematopoietic stem cell transplantation in CML
YJ Kim, DW Kim, S Lee, HJ Kim, YL Kim… - European journal of …, 2002 - Wiley Online Library
The reverse transcriptase‐polymerase chain reaction (RT‐PCR) was compared with
fluorescence in situ hybridization (FISH) and real‐time quantitative RT‐PCR (RQ‐PCR) for …
fluorescence in situ hybridization (FISH) and real‐time quantitative RT‐PCR (RQ‐PCR) for …
Assessment of the response to imatinib in chronic myeloid leukemia patients–comparison between the FISH, multiplex and RT‐PCR methods
P Raanani, I Ben‐Bassat, S Gan… - European journal of …, 2004 - Wiley Online Library
Objective: The objective of this study was to evaluate the kinetics of molecular response in
chronic myeloid leukemia (CML) patients treated with imatinib and to compare between the …
chronic myeloid leukemia (CML) patients treated with imatinib and to compare between the …
Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra signals
B Mohr, M Bornhäuser, U Platzbecker… - Cancer genetics and …, 2001 - Elsevier
Interphase fluorescence in situ hybridization (I-FISH) is frequently used to monitor the
response to therapy in various hematological malignancies. We performed a comparison of I …
response to therapy in various hematological malignancies. We performed a comparison of I …
Chronic myelogenous leukemia
UR Osarogiagbon, PB McGlave - Current opinion in hematology, 1999 - journals.lww.com
Over the past year, new information has been reported on the biology and treatment of
chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by …
chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by …
Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission
A Kitzis, F Brizard, C Dascalescu, JC Chomel… - Leukemia & …, 2001 - Taylor & Francis
Persistence of BCR-ABL rearrangements was demonstrated by D-FISH technique in chronic
myeloid leukemia (CML) patients in complete cytogenetic response (CCR) after allogeneic …
myeloid leukemia (CML) patients in complete cytogenetic response (CCR) after allogeneic …